Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard Anti-epileptic drug (SAED) in the treatment of epilepsy

a technology of phytocannabinoid cannabidiol and epilepsy, which is applied in the direction of biocide, plant/algae/fungi/lichens, drug compositions, etc., can solve the problems that the selective benefits of cbd with e.g. ethosuximide and valporate (saed's with defined sodium channels) cannot be anticipated, and achieve the effect of reducing the severity and mortality of seizures

Inactive Publication Date: 2014-06-05
GW PHARMA LTD +1
View PDF0 Cites 62 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The CBD-SAED combination demonstrates significant benefits in reducing seizure incidence, increasing seizure-free time, and decreasing seizure severity and mortality in both PTZ-induced and pilocarpine models of epilepsy, particularly for generalized and temporal lobe seizures, offering a new approach for refractory epilepsy cases.

Problems solved by technology

Thus, the selective benefits of CBD with e.g. ethosuximide and valporate (SAED's with defined and distinct mechanisms of actions involving calcium and sodium channels) could not be anticipated.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard Anti-epileptic drug (SAED) in the treatment of epilepsy
  • Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard Anti-epileptic drug (SAED) in the treatment of epilepsy
  • Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard Anti-epileptic drug (SAED) in the treatment of epilepsy

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0070]The Use of the Phytocannabinoid CBD in Combination with a Standard Anti-Epileptic Drug (SAED) in the PTZ-Model of Epilepsy

Methodology:

Animals:

[0071]Male Wistar rats (P24-29; 75-110 g) were used to assess the effects of the phytocannabinoid CBD in combination with SAEDs in the PTZ model of generalised seizures. Animals were habituated to the test environment, cages, injection protocol and handling prior to experimentation. Animals were housed in a room at 21° C. on a 12 hour light: dark cycle (lights on 0900) in 50% humidity, with free access to food and water.

[0072]The human dose equivalent (HED) can be estimated using the following formula:

HED=Animaldose(mg / kg)multipliedbyAnimalKmHumanKm[0073]The Km for a rat is 6 and the Km for a human is 37.

Thus, for a human of approx 60 Kg a 100 mg / Kg dose in rat would equate to a human dose of about 1000 mg. Human doses of greater than 300 mg / day, through 400 mg / day in 100 mg intervals (namely through 500, 600, 700, 800, 900, 1000, 1100, ...

example 2

[0088]The Use of the Phytocannabinoid CBD in Combination with a Standard Anti-Epileptic Drug (SAED) in the Pilocarpine Model of (Temporal Lobe) Epilepsy

Methodology:

[0089]Isolated CBD was injected intra-peritoneally (IP) in the standard vehicle (1:1:18 ethanol:Cremophor:0.9% w / v NaCl) at doses of 50, 100 and 200 mg / kg alongside animals that received vehicle alone at a matched volume. 15 minutes later methylscopolamine (1 mg / kg; to reduce peripheral muscarinic effects of pilocarpine) was administered followed, 45 minutes later by pilocarpine (380 mg / kg, IP) administration.

Results:

[0090]FIG. 4 demonstrates the anti-convulsant effects of a combination of CBD and valproate in the pilocarpine model of epilepsy. These data show that the combination of the CBD and valproate was able to increase the latency of onset of the seizure.

[0091]It can be seen from the data illustrated in FIG. 5 that in addition to increasing the latency of onset of the seizure the combination of CBD and valproate wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
humidityaaaaaaaaaa
action potentialsaaaaaaaaaa
refractoryaaaaaaaaaa
Login to View More

Abstract

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg / day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

Description

[0001]This invention relates to the use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED). Preferably the CBD is used in combination with a SAED with a mechanism of action which acts via sodium or calcium channels, more preferably one which:[0002]modifies low-threshold or transient neuronal calcium currents, as exemplified by ethosuximide; or[0003]reduces high-frequency neuronal firing and sodium-dependent action potentials and may additionally enhance GABA effects, as exemplified by valproate.BACKGROUND[0004]Epilepsy is a chronic neurological disorder presenting a wide spectrum of diseases that affect approximately 50 million people worldwide (Sander, 2003). Advances in the understanding of the body's internal ‘endocannabinoid’ system has lead to the suggestion that cannabis-based medicines may have the potential to treat this disorder of hyperexcitability in the central nervous system (Mackie, 2006, Wingerchuk, 2004, Alger, 2006).[...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/05A61K31/4015A61K31/19A61K45/06
CPCA61K31/05A61K31/19A61K31/4015A61K45/06A61K2300/00A61K31/352A61K31/515A61P25/08A61K36/185A61K36/00
Inventor WHALLEY, BENWILLIAMS, CLAIRESTEPHENS, GARY
Owner GW PHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com